| P50 | author | Parco M. Siu | Q54954974 |
| P2093 | author name string | S S Yu | |
| | K S Chan | |
| | A P Yu | |
| | W Y Yau | |
| | B T Tam | |
| | T L Chung | |
| P2860 | cites work | Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 | Q27860575 |
| | Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 |
| | Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults | Q28131763 |
| | Endothelin-1 in congenital heart disease | Q28244078 |
| | High glucose-induced increased expression of endothelin-1 in human endothelial cells is mediated by activated CCAAT/enhancer-binding proteins | Q28537960 |
| | Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation | Q29547453 |
| | The metabolic syndrome--a new worldwide definition | Q29615125 |
| | Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition | Q29615691 |
| | Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement | Q29619465 |
| | A novel potent vasoconstrictor peptide produced by vascular endothelial cells | Q29620540 |
| | Chronic vasodilation induces matrix metalloproteinase 9 (MMP-9) expression during microvascular remodeling in rat skeletal muscle | Q30307203 |
| | Matrix metalloproteinases in subjects with type 1 diabetes | Q33503886 |
| | Role of endothelin 1 in the pathogenesis of chronic chagasic heart disease | Q33769435 |
| | Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone | Q33984832 |
| | Role of matrix metalloproteinase-9 in the development of diabetic retinopathy and its regulation by H-Ras | Q34022639 |
| | Transgenic mice over-expressing ET-1 in the endothelial cells develop systemic hypertension with altered vascular reactivity | Q34077735 |
| | Regular consumption of vitamin D-fortified yogurt drink (Doogh) improved endothelial biomarkers in subjects with type 2 diabetes: a randomized double-blind clinical trial | Q34083005 |
| | Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2 | Q34084599 |
| | Symposium introduction: metabolic syndrome and the onset of cancer | Q34088014 |
| | Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus | Q34142970 |
| | Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice | Q34236802 |
| | Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition | Q34545044 |
| | Mechanisms of obesity-associated cardiovascular and renal disease | Q34870994 |
| | Endothelin-1 enhances neutrophil adhesion to human coronary artery endothelial cells: role of ET(A) receptors and platelet-activating factor | Q35028995 |
| | Endothelin-1: a multifunctional molecule in cancer | Q35074833 |
| | The link between the metabolic syndrome and cancer | Q35187561 |
| | Blood pressure control predicts plasma matrix metalloproteinase-9 in diabetes mellitus type II. | Q35232260 |
| | Metabolic syndrome and cancer | Q35319301 |
| | CCR5 facilitates endothelial progenitor cell recruitment and promotes the stabilization of atherosclerotic plaques in ApoE-/- mice. | Q35503935 |
| | Endothelin-1 critically influences cardiac function via superoxide-MMP9 cascade | Q35549144 |
| | Endothelin receptor blockers in cardiovascular disease | Q35575498 |
| | Endothelin-1 stimulates human colonic myofibroblast contraction and migration | Q35594307 |
| | Effects of 1-year yoga on cardiovascular risk factors in middle-aged and older adults with metabolic syndrome: a randomized trial. | Q35632791 |
| | The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia | Q35780951 |
| | Matrix Metalloproteinase 9 Gene Promoter (rs 3918242) Mutation Reduces the Risk of Diabetic Microvascular Complications | Q35891015 |
| | Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture | Q35993294 |
| | Metalloproteinases and their inhibitors in tumor angiogenesis | Q36053766 |
| | Metabolic syndrome and risk of cancer: a systematic review and meta-analysis | Q36334568 |
| | Obesity and risk of non-Hodgkin's lymphoma: a meta-analysis | Q36795379 |
| | Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. | Q36863958 |
| | The importance of endothelin-1 for vascular dysfunction in cardiovascular disease | Q36872995 |
| | The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression | Q36898979 |
| | HDL-cholesterol and incidence of breast cancer in the ARIC cohort study | Q36934633 |
| | Mechanisms of ET-1-induced endothelial dysfunction | Q37037144 |
| | Biomarkers in Acute Coronary Syndrome | Q37207294 |
| | Role of endothelin-1 in clinical hypertension: 20 years on. | Q37234843 |
| | Relations of matrix remodeling biomarkers to blood pressure progression and incidence of hypertension in the community | Q37312630 |
| | Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. | Q37380847 |
| | Overexpression of endothelin 1 triggers hepatocarcinogenesis in zebrafish and promotes cell proliferation and migration through the AKT pathway | Q37453166 |
| | Obesity-related hypertension. | Q37878315 |
| | Metabolic syndrome and risk of cardiovascular disease: a meta-analysis | Q39015722 |
| | Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. | Q42757110 |
| | Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress | Q43649151 |
| | Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy | Q43786938 |
| | Plasma profiles of peripheral monocyte-related inflammatory markers in patients with arterial hypertension. Correlations with plasma endothelin-1. | Q43963228 |
| | Effect of obesity on survival in epithelial ovarian cancer | Q44049581 |
| | Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. | Q44323041 |
| | Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk | Q45006133 |
| | VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. | Q45118767 |
| | Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia | Q46069121 |
| | Matrix metalloproteinase-9 in spontaneously hypertensive hyperlipidemic rats | Q46590543 |
| | Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study | Q46917101 |
| | Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. | Q47270384 |
| | Endothelin-1 upregulation mediates aging-related cardiac fibrosis | Q48135488 |
| | Plasma levels of matrix metalloproteinase-9 are independently associated with psychosocial factors in a middle-aged normal population. | Q50758311 |
| | Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. | Q51033461 |
| | Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. | Q53617689 |
| | Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. | Q54117687 |
| | Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men | Q57416307 |
| | Epidemiology and risk of hypertension in the elderly: the Framingham Study | Q68014602 |
| | Plasma endothelin levels in hypertension and chronic renal failure | Q68506843 |
| | Central obesity and hypertension: the role of plasma endothelin | Q71915235 |
| | Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma | Q73151042 |
| | Endothelins are angiogenic | Q73189994 |
| | Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines | Q73454316 |
| | Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells | Q73595175 |
| | Elevated plasma endothelin-1 levels in diabetes mellitus | Q78541880 |
| | [Cardiovascular disease in diabetes mellitus: classical and non-classical risk factors] | Q80342550 |
| | Role of matrix metalloproteinases in early hypertensive vascular remodeling | Q80361644 |
| | Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension | Q81269369 |
| P921 | main subject | metabolic syndrome | Q657193 |
| P304 | page(s) | 111 | |
| P577 | publication date | 2015-12-10 | |
| P1433 | published in | Diabetology and Metabolic Syndrome | Q15816649 |
| P1476 | title | Association of endothelin-1 and matrix metallopeptidase-9 with metabolic syndrome in middle-aged and older adults | |
| P478 | volume | 7 | |